We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$563M
Cap. Flow
+$217M
Cap. Flow %
4.4%
Top 10 Hldgs %
40.18%
Holding
111
New
29
Increased
28
Reduced
20
Closed
14
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$126M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$95.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$76.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$72.2M
5
PRTA icon
Prothena Corp
PRTA
+$62.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$186M
2
JNJ icon
Johnson & Johnson
JNJ
+$160M
3
MCK icon
McKesson
MCK
+$127M
4
UNH icon
UnitedHealth
UNH
+$124M
5
ABBV icon
AbbVie
ABBV
+$116M

Sector Composition

Rank Sector Weight
1 Healthcare 90.59%
2 Miscellaneous 8.92%
3 Financials 0.49%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CTLT icon
26
DELISTED
CATALENT, INC.
CTLT
$68M 1.38%
940,000
-15,000
-2% -$1.49M
2020 Q3
8 quarters
ITCI icon
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$65.3M 1.33%
1,402,500
+626,996
+81% +$32.8M
2022 Q2
1 quarter
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$61M 1.24%
445,500
-104,500
-19% -$17M
2021 Q1
6 quarters
BIO icon
29
Bio-Rad Laboratories Class A
BIO
$9.46B
$60.4M 1.23%
+144,800
New +$72.2M
2022 Q3
0 quarters
ALNY icon
30
Alnylam Pharmaceuticals
ALNY
$31B
$57.7M 1.17%
+288,500
New +$55M
2022 Q3
0 quarters
APLS icon
31
DELISTED
Apellis Pharmaceuticals
APLS
$57.6M 1.17%
844,000
+629,000
+293% +$37.2M
2022 Q1
2 quarters
NTLA icon
32
Intellia Therapeutics
NTLA
$1.6B
$55.9M 1.14%
999,100
-126,094
-11% -$7.82M
2022 Q1
2 quarters
IDYA icon
33
IDEAYA Biosciences
IDYA
$3.17B
$55.4M 1.13%
3,715,400
+742,453
+25% +$9.64M
2021 Q1
6 quarters
KZR icon
34
DELISTED
Kezar Life Sciences
KZR
$46.6M 0.95%
541,440
+136,440
+34% +$13.3M
2021 Q3
4 quarters
BLU
35
DELISTED
BELLUS Health Inc.
BLU
$45.9M 0.93%
4,346,700
+81,700
+2% +$868K
2020 Q4
7 quarters
RVMD icon
36
Revolution Medicines
RVMD
$38.1B
$45.8M 0.93%
2,321,200
+996,200
+75% +$21.9M
2022 Q2
1 quarter
RNAM
37
DELISTED
Avidity Biosciences
RNAM
$42.5M 0.86%
2,600,000
+519,800
+25% +$9.94M
2021 Q3
4 quarters
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$13.6B
$42.4M 0.86%
318,300
+256,300
+413% +$39M
2022 Q2
1 quarter
ZLAB icon
39
Zai Lab
ZLAB
$2.6B
$42.2M 0.86%
+1,234,000
New +$52.8M
2022 Q3
0 quarters
ARWR icon
40
Arrowhead Research
ARWR
$7.9B
$41.5M 0.84%
1,255,374
-183,625
-13% -$7.41M
2021 Q2
5 quarters
PLRX icon
41
Pliant Therapeutics
PLRX
$55.7M
$41.4M 0.84%
+1,981,100
New +$37.9M
2022 Q3
0 quarters
DXCM icon
42
DexCom
DXCM
$32.5B
$37.7M 0.77%
+467,600
New +$39.6M
2022 Q3
0 quarters
SYK icon
43
Stryker
SYK
$113B
$37.4M 0.76%
+184,700
New +$38.9M
2022 Q3
0 quarters
VERV icon
44
DELISTED
Verve Therapeutics
VERV
$35.8M 0.73%
+1,042,706
New +$33.3M
2022 Q3
0 quarters
ALT icon
45
Altimmune
ALT
$428M
$34.3M 0.7%
2,684,000
-297,000
-10% -$4.39M
2021 Q3
4 quarters
CNC icon
46
Centene
CNC
$34.2B
$33.6M 0.68%
+432,400
New +$38.6M
2022 Q3
0 quarters
CRBU icon
47
Caribou Biosciences
CRBU
$50.4M
$33.5M 0.68%
3,172,600
+222,600
+8% +$2.07M
2021 Q3
4 quarters
AZN icon
48
AstraZeneca
AZN
$257B
$30.9M 0.63%
281,600
-1,467,900
-84% -$186M
2021 Q3
4 quarters
NGM
49
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$23.5M 0.48%
+1,798,100
New +$27.2M
2022 Q3
0 quarters
DCPH icon
50
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$22M 0.45%
1,191,800
-8,200
-0.7% -$129K
2022 Q2
1 quarter
1
2
3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q3 2022 Portfolio in Review

As of Q3 2022, Avidity Partners Management held 111 positions worth $4.92B, up 13% from $4.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $217M of net new capital in Q3 2022, opening 29 new positions and adding to 28 existing holdings. Its largest new stake was Sarepta Therapeutics: 948,200 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $186M trimmed.

  • Avidity Partners Management's largest Q3 2022 buy was Sarepta Therapeutics: 948,200 shares worth $105M.
  • Avidity Partners Management added most to Eli Lilly in Q3 2022, an estimated $126M increase.
  • Avidity Partners Management's biggest Q3 2022 reduction was AstraZeneca, cutting an estimated $186M.
  • Avidity Partners Management fully exited Johnson & Johnson in Q3 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.92B portfolio in Q3 2022.
  • Avidity Partners Management opened 29 new positions and closed 14 in Q3 2022.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $4.92B.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.